Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 Biomarker disease BEFREE In summary, amongst the n3-PUFA, DHA was the most effective for elevating hepatic DHA levels, and preventing progression of hepatic steatosis via reductions in FAS and a marker of fibrosis. 31022865 2019
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 AlteredExpression disease BEFREE Overexpression of SIK1 improved hyperglycaemia, hyperlipidaemia and fatty liver, reduced the expression of cAMP-response element binding protein (CREB)-regulated transcription co-activator 2 (CRTC2), phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase), pS577 SIK1, sterol regulatory element binding-protein-1c (SREBP-1c) and its target genes, including acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), and increased the expression of SIK1, pT182 SIK1 and pS171 CRTC2 in diabetic rat livers with the suppression of gluconeogenesis and lipid deposition. 31233505 2019
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 AlteredExpression disease BEFREE FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice. 31110049 2019
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 Biomarker disease BEFREE Correction: The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys. 28103304 2019
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 Biomarker disease BEFREE It also reduced expression of the lipogenic genes fatty acid synthase (FAS) and 3-hydroxy-3-methylglutarylCoA reductase (HMGCR), alleviated hepatic steatosis, improved glucose tolerance, elevated insulin sensitivity, and activated insulin receptor substrate (IRS)2/Akt signaling in vivo and/or in vitro. 29575055 2018
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 AlteredExpression disease BEFREE To investigate [<sup>11</sup>C]acetate PET-surrogate parameter of fatty acid synthase activity-as suitable tool for diagnosis and monitoring of liver steatosis. 29644441 2018
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 Biomarker disease BEFREE FK866 significantly promoted liver steatosis in the mice fed with HFD and hepatic lipid accumulation in vitro, accompanied by the increases of the expressions of lipogenic genes such as sterol regulatory element-binding protein 1 (SREBP1) and fatty acid synthase (FASN). 28449683 2017
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 AlteredExpression disease BEFREE MiR-30c-5p ameliorates hepatic steatosis in leptin receptor-deficient (db/db) mice via down-regulating FASN. 28088781 2017
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 Biomarker disease BEFREE Study 1 focused on regulation by five transcription factors (TFs) (NfKb, Srebp-lc, AMPK, PPARα, PPARγ) of seven, much-studied hepatic long-chain fatty acid (LCFA) transporters (FABPpm, CD36, FATPl, FATP2, FATP4, FATP5, & Caveolin-1 [CAV-1]), and expression of genes for enzymes of LCFA synthesis (SCD-1, FASN) in mice with HS from various causes. 27997977 2016
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 Biomarker disease BEFREE We report here that the development of hepatic steatosis requires IL-1 signaling, which upregulates Fatty acid synthase to promote hepatic lipogenesis. 25216251 2014
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 AlteredExpression disease BEFREE Real-time quantitative PCR and western blotting were used to detect the expression levels of FASN and its downstream proteins liver fatty acid-binding protein (L-FABP) and VEGF/VEGFR-2 in both in vitro and in vivo models (nude mouse tumor tissues). 24520215 2014
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 AlteredExpression disease BEFREE On the other hand, we observed that expression of miR-130a-3p is decreased in the livers of db/db mice and that adenovirus-mediated overexpression of miR-130a-3p reverses insulin resistance and liver steatosis, the latter of which is achieved via suppressing fatty acid synthase expression in these mice. 24677715 2014